首页> 外文OA文献 >Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
【2h】

Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

机译:组织纤溶酶原激活剂(tPA)抑制纤维蛋白的纤溶酶降解。一种机制,可以减慢tPA介导的纤维蛋白溶解的速度,但不需要alpha 2-抗纤溶酶或内源性纤溶酶原的泄漏。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thrombolysis is dramatically slower when high concentrations of lytic agent are used. This paradoxical observation, first described as "plasminogen steal," was originally believed to be due to depletion of extrinsic plasminogen and consequent leaching of clot-bound plasminogen. We report that administration of increasing concentrations of recombinant human tissue plasminogen activator (tPA) to fibrin gels resulted in lysis rates that displayed a maximum, with significantly slower rates found at higher tPA, regardless of whether plasminogen was supplied extrinsically or intrinsically. A similar maximum in lysis rates was observed in a system lacking an extrinsic phase when plasminogen was added to fibrin suspensions preincubated with increasing tPA. Thus, intrinsic plasminogen leakage and alpha 2-antiplasmin were not required for the decreased lysis at high tPA. No maximum was observed for increasing concentrations of urokinase. Using fibrin suspensions or gels preincubated with tPA before addition of plasmin, we report that tPA, but not urokinase, caused a dose-dependent inhibition of the fibronolytic action of plasmin. With respect to optimal dosage schemes and the design of novel lytic agents, these findings indicate that (a) there exists a biochemical mechanism against minimizing reperfusion time with increasing tPA dosages and (b) the fibrin affinity of tPA may cause reduced fibrinolysis by plasmin.
机译:当使用高浓度的溶解剂时,溶栓会明显变慢。最初被认为是这种“自相矛盾的发现”,最初被认为是由于外源性纤溶酶原的耗竭和凝结结合的纤溶酶原的浸出所致。我们报告说,增加浓度的重组人组织纤溶酶原激活物(tPA)到纤维蛋白凝胶的施用导致裂解速率显示出最大值,而更高的tPA则显示出明显较慢的裂解速率,无论纤溶酶原是由外部还是内部提供。当将纤溶酶原添加到以增加的tPA进行预温育的纤维蛋白悬浮液中时,在缺乏外部相的系统中观察到了相似的最大裂解速率。因此,内在的纤溶酶原渗漏和α2-抗纤溶酶对于高tPA时的裂解减少是不需要的。尿激酶浓度增加未观察到最大值。在添加纤溶酶之前,使用纤维蛋白悬浮液或与tPA预先孵育的凝胶,我们报道tPA而非尿激酶引起纤溶酶的纤溶作用的剂量依赖性抑制。关于最佳剂量方案和新型溶解剂的设计,这些发现表明:(a)存在一种生物化学机制,可通过增加tPA剂量来最大程度地减少再灌注时间;(b)tPA的血纤蛋白亲和力可能会导致纤溶酶的血纤蛋白溶解降低。

著录项

  • 作者

    Wu, J H; Diamond, S L;

  • 作者单位
  • 年度 1995
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号